https://www.nioublinipardon.com/category/institutions/swissmedic/
Swissmedic – Ni Oubli Ni Pardon
swissmedicnioublipardon
https://www.swissmedic.ch/swissmedic/en/home/about-us/publications/swissmedic-journal/swissmedic-journal-2005.html
Swissmedic Journal 2005
swissmedicjournal
https://www.masuuglobal.com/swissmedic-nitrosamine-risk-assessment-requirements/
Swissmedic Nitrosamine Risk Assessment Requirements
May 16, 2025 - Learn Swissmedic's updated nitrosamine risk assessment requirements for new authorizations of active substances and medicinal products.
risk assessmentswissmedicrequirements
https://www.swissmedic.ch/swissmedic/fr/home/notre-profil/publications/swissmedic-journal/journal-swissmedic-2007.html
Journal Swissmedic 2007
journalswissmedic
https://pmc.ncbi.nlm.nih.gov/articles/PMC10764525/
An Evaluation of the Swissmedic Regulatory Framework for New Active Substances - PMC
Swissmedic is a major regulatory agency that has been benchmarking its timelines for 20 years. To better understand the Swissmedic review times and to examine...
of theregulatory framework
https://acheter-peptides.fr/blog/reglementation-peptides-recherche-suisse
Peptides Suisse 2026 : Réglementation et Swissmedic
Apr 4, 2026 - Réglementation peptides recherche Suisse 2026 : cadre Swissmedic, listes de substances contrôlées et statut juridique des peptides synthétiques in vitro.
peptidessuisseetswissmedic
https://www.biopharmaapac.com/news/33/5409/csl-vifor-and-travere-therapeutics-secure-swissmedic-approval-for-filspari-in-treatment-of-iga-nephropathy.html
CSL Vifor and Travere Therapeutics Secure Swissmedic Approval for FILSPARI in Treatment of IgA...
CSL Vifor and Travere Therapeutics Secure Swissmedic Approval for FILSPARI in Treatment of IgA Nephropathy
https://www.masuuglobal.com/swissmedic-updated-m1-specification-v1-4-and-ectd-validation-criteria-v1-4/
SWISSmedic updated M1 Specification (v1.4) and eCTD Validation Criteria (v1.4) - Masuu Global
Jul 10, 2024 - On 01 January 2019 the new Swiss Module 1 Specification for eCTD v1.4 is implemented. Both versions (v1.3 and v1.4) will be valid for a half-year period from...